101 related articles for article (PubMed ID: 30992301)
1. A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Advani AS; Cooper B; Visconte V; Elson P; Chan R; Carew J; Wei W; Mukherjee S; Gerds A; Carraway H; Nazha A; Hamilton B; Sobecks R; Caimi P; Tomlinson B; Malek E; Little J; Miron A; Pink J; Maciejewski J; Unger A; Kalaycio M; de Lima M; Sekeres MA
Clin Cancer Res; 2019 Jul; 25(14):4231-4237. PubMed ID: 30992301
[TBL] [Abstract][Full Text] [Related]
2. Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study.
Pardee TS; Luther S; Buyse M; Powell BL; Cortes J
Future Oncol; 2019 Oct; 15(28):3197-3208. PubMed ID: 31512500
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
Zhong S; Kurish H; Walchack R; Li H; Edwards J; Singh A; Advani A
Leuk Res; 2024 Apr; 139():107468. PubMed ID: 38460433
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
DeAngelo DJ; Jonas BA; Liesveld JL; Bixby DL; Advani AS; Marlton P; Magnani JL; Thackray HM; Feldman EJ; O'Dwyer ME; Becker PS
Blood; 2022 Feb; 139(8):1135-1146. PubMed ID: 34543383
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
Pardee TS; Anderson RG; Pladna KM; Isom S; Ghiraldeli LP; Miller LD; Chou JW; Jin G; Zhang W; Ellis LR; Berenzon D; Howard DS; Hurd DD; Manuel M; Dralle S; Lyerly S; Powell BL
Clin Cancer Res; 2018 May; 24(9):2060-2073. PubMed ID: 29437791
[No Abstract] [Full Text] [Related]
6. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
Greenberg PL; Lee SJ; Advani R; Tallman MS; Sikic BI; Letendre L; Dugan K; Lum B; Chin DL; Dewald G; Paietta E; Bennett JM; Rowe JM
J Clin Oncol; 2004 Mar; 22(6):1078-86. PubMed ID: 15020609
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Bhatnagar B; Zhao Q; Mims AS; Vasu S; Behbehani GK; Larkin K; Blachly JS; Badawi MA; Hill KL; Dzwigalski KR; Phelps MA; Blum W; Klisovic RB; Ruppert AS; Ranganathan P; Walker AR; Garzon R
Leuk Lymphoma; 2023 Dec; 64(13):2091-2100. PubMed ID: 37665178
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
Wang AY; Weiner H; Green M; Chang H; Fulton N; Larson RA; Odenike O; Artz AS; Bishop MR; Godley LA; Thirman MJ; Kosuri S; Churpek JE; Curran E; Pettit K; Stock W; Liu H
J Hematol Oncol; 2018 Jan; 11(1):4. PubMed ID: 29304833
[TBL] [Abstract][Full Text] [Related]
9. Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Garcia JS; Bhatt S; Fell G; Sperling AS; Burgess M; Keshishian H; Yilma B; Brunner A; Neuberg D; Carr SA; Ebert BL; Ballen K; Stone RM; DeAngelo DJ; Medeiros BC; Letai A
Am J Hematol; 2020 Mar; 95(3):245-250. PubMed ID: 31804723
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse.
Im A; Amjad A; Agha M; Raptis A; Hou JZ; Farah R; Lim S; Sehgal A; Dorritie KA; Redner RL; McLaughlin B; Shuai Y; Duggal S; Boyiadzis M
Oncol Res; 2016; 24(2):73-80. PubMed ID: 27296947
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J; Zwiebel JA; Devine S; Byrd JC; Grever MR; Chan K; Marcucci G
Clin Cancer Res; 2008 Jun; 14(12):3889-95. PubMed ID: 18559610
[TBL] [Abstract][Full Text] [Related]
12. Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
Kopmar NE; Gooley T; Curley N; Russell K; Shaw C; Schonhoff K; Lim J; Halpern AB; Walter RB; Scott BL; Appelbaum J; Hendrie PC; Estey EH; Percival MM
Leuk Lymphoma; 2023 May; 64(5):1057-1059. PubMed ID: 36896478
[No Abstract] [Full Text] [Related]
13. A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia.
Gera K; Cline C; Al-Mansour Z; Medvec A; Lee JH; Galochkina Z; Hsu J; Hiemenz J; Farhadfar N; Dean EA; Wingard JR; Brown R
Leuk Lymphoma; 2024 Jun; ():1-9. PubMed ID: 38841781
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts.
Randall J; Evans K; Watts B; Kosasih HJ; Smith CM; Earley EJ; Erickson SW; Jocoy EL; Bult CJ; Teicher BA; de Bock CE; Smith MA; Lock RB
Exp Hematol; 2024 Apr; 132():104176. PubMed ID: 38320689
[TBL] [Abstract][Full Text] [Related]
15. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study.
Baron F; Efficace F; Cannella L; Muus P; Trisolini S; Halkes CJM; Fazi P; Vignetti M; Marie JP; Chiusolo P; van der Velden W; La Sala E; Vitolo U; Thomas X; Lefrère F; Di Raimondo F; Bourhis JH; Specchia G; Guimarães JE; Allione B; Vrhovac R; Ferrara F; Stevens-Kroef M; Meert L; de Witte T; Willemze R; Amadori S; Suciu S
Am J Hematol; 2020 Jul; 95(7):749-758. PubMed ID: 32233095
[TBL] [Abstract][Full Text] [Related]
16. Gilteritinib or Chemotherapy for Relapsed or Refractory
Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
[TBL] [Abstract][Full Text] [Related]
17. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
18. IFI30 Is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma.
Zhu C; Chen X; Guan G; Zou C; Guo Q; Cheng P; Cheng W; Wu A
Onco Targets Ther; 2020; 13():1129-1143. PubMed ID: 32103982
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.
Shallis RM; Wang R; Davidoff A; Ma X; Zeidan AM
Blood Rev; 2019 Jul; 36():70-87. PubMed ID: 31101526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
